Safety Study of JTT-302 in Subjects With Low HDL-C Levels

Completed · Phase 2

Conditions studied: Dyslipidemia

In brief

The purpose of this study is to evaluate the safety of JTT-302 when administered for eight or 12 weeks in subjects with low HDL-C levels and to determine the effect of JTT-302 on lipid parameters and CETP activity and mass.

Key facts

Study ID

NCT00748852

Run by

Akros Pharma Inc.

People needed

103

Starts

2007-01-01

Expected to finish

2008-03-01

Last updated by the study team

2013-02-04

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects must have successfully completed the 4-week treatment period of study AT302-U-06-003

You may not qualify if…

• Females who are pregnant or lactating, and females of child bearing potential who are not using an effective method of contraception
• Use of Cytochrome P450 3A4 inducers or inhibitors, as defined in the protocol
• Subjects who cannot follow the prescription and OTC medication restrictions defined in the protocol
• Flu-shots not permitted during the study, including the follow-up period.

Where it is running

• Study site — Santa Ana, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.